Qishenyiqi dripping pills
Phase 3Small molecule
Qishenyiqi dripping pills is one of 70 small molecule programs targeting Myocardial Infarction. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Myocardial Infarction
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Farxiga
AstraZenecaApproved
Repatha
AmgenApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Crestor
AstraZenecaApproved
Praluent
RegeneronApproved
Neoral
NovartisApproved
Aldactone
PfizerApproved
Zocor
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Qishenyiqi dripping pills. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details